Read More Pharma Industry News TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience. bySrinathMay 16, 2026